>_ QFI Terminal
TerminalStocks › XAIR

Beyond Air, Inc. (XAIR) Stock

Healthcare · Medical - Devices · US
$4.39 -22.98%
Last updated Sep 20, 2026 15:00 UTC

XAIR Key Statistics

Market Cap$22.25M
P/E (TTM)-0.81
P/S (TTM)3.21
P/B (TTM)4.57
Revenue (TTM)$6.92M
EPS (TTM)$-5.42
Dividend Yield
ROE (TTM)-279.58%
Net Margin-447.73%
Gross Margin1.82%
52W High$10.50
52W Low$0.61
Analyst ViewBuy
Price Target$1.00
Employees107
Volume157,351

About Beyond Air, Inc.

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

CEO: Amir Avniel. Company website

XAIR — Frequently Asked Questions

What is the XAIR stock price today?

Beyond Air, Inc. (XAIR) trades at $4.39, down 22.98% on the day, as of Sep 20, 2026 15:00 UTC.

What is Beyond Air, Inc.'s market cap?

Beyond Air, Inc. has a market capitalisation of $22.25M, calculated from the live XAIR share price and shares outstanding.

What is the P/E ratio of XAIR?

XAIR has no meaningful price-to-earnings ratio: Beyond Air, Inc. lost $5.42 per share over the last twelve months, and a P/E is only defined on positive earnings.

How much revenue does Beyond Air, Inc. make?

Beyond Air, Inc. generated revenue of $6.92M over the trailing twelve months, which puts the stock at 3.21 times sales.

What is the 52-week range for XAIR?

XAIR has traded between $0.61 and $10.50 over the past 52 weeks, and the last price is 58.2% below that high.

Is Beyond Air, Inc. profitable?

No. Beyond Air, Inc. is loss-making, with a net margin of -447.73% over the trailing twelve months.

What is the analyst price target for XAIR?

Wall Street analysts rate XAIR Buy, with an average price target of $1.00, 77.2% below the current price.

What sector is Beyond Air, Inc. in?

Beyond Air, Inc. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US .

Who is the CEO of Beyond Air, Inc.?

Amir Avniel is the chief executive of Beyond Air, Inc., which employs 107 people.

Where can I track XAIR in real time?

QFI Terminal shows XAIR with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See XAIR live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open XAIR in Terminal See plans

Medical - Devices stocks

ABT Abbott Laboratories MDT Medtronic plc SYK Stryker Corporation BSX Boston Scientific Corporation GEHC GE HealthCare Technologies Inc. ZBH Zimmer Biomet Holdings, Inc. EW Edwards Lifesciences Corporation SNN Smith & Nephew plc

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.